Job title: Principal Scientist
Donglu Zhang is interested in applying drug metabolism studies in drug design and development of both small molecule drugs and antibody-drug conjugates (ADCs). He received the Sir James Black Award for discovery of and original research on Eliquis from British Pharmacological Society (2018) and the Ondetti and Cushman Award for invention of mass defect filtering method (MDF) from Bristol-Myers Squibb (2007). He is on Editorial Board of Drug Metabolism and Disposition and Xenobiotica. He edited two textbooks ‘Drug metabolism in drug design and development’, and ‘ADME-enabling technologies in drug design and development’. He received a Ph.D. in Organic Chemistry from University of Utah.